MATHEW JOSEPH
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology DICKSON, TN NPI 1922280692
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TN Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$12,073.99
- Category: General Payments
- Program years: PY2018–2024
- Record count: 461
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,617.30 across 66 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,517.55 | 65 |
| Education | $99.75 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $148.23 | 3 |
| PFIZER INC. | $127.01 | 6 |
| Acerta Pharma LLC | $94.27 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $93.35 | 5 |
| Amgen Inc. | $90.85 | 1 |
| ABBVIE INC. | $90.37 | 4 |
| Regeneron Healthcare Solutions, Inc. | $72.87 | 3 |
| Janssen Biotech, Inc. | $69.95 | 3 |
| E.R. Squibb & Sons, L.L.C. | $58.87 | 3 |
| GENZYME CORPORATION | $57.41 | 2 |
| EISAI INC. | $52.23 | 2 |
| GlaxoSmithKline, LLC. | $50.32 | 2 |
| Incyte Corporation | $49.40 | 2 |
| Merck Sharp & Dohme Corporation | $48.55 | 2 |
| JAZZ PHARMACEUTICALS INC. | $47.29 | 2 |
| Exelixis Inc. | $45.56 | 2 |
| PharmaEssentia USA Corporation | $45.49 | 2 |
| Gilead Sciences, Inc. | $42.92 | 2 |
| BeiGene USA, Inc. | $40.22 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $37.55 | 2 |
| Rigel Pharmaceuticals, Inc. | $35.66 | 2 |
| Celgene Corporation | $31.66 | 2 |
| Lilly USA, LLC | $31.03 | 1 |
| AVEO Pharmaceuticals, Inc. | $27.26 | 1 |
| TAIHO ONCOLOGY, INC. | $26.76 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $24.42 | 1 |
| TerSera Therapeutics LLC | $22.17 | 1 |
| ARRAY BIOPHARMA INC | $21.73 | 1 |
| Mirati Therapeutics, Inc. | $19.88 | 1 |
| Genentech USA, Inc. | $14.02 | 1 |
By program year
Records — PY2024 (66)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.